Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Adzynma Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy CSOH2026D00131.E

    Adzynma (ADAMTS13, Recombinant-Krhn) (for Ohio Only)

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CSOH2026D00131.E alerts

    Get alerted when Policy CSOH2026D00131.E changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Ohio-only medical benefit drug policy governing coverage and prior authorization for Adzynma in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.

    Policy Summary
    PayerUnitedHealthcare
    PolicyAdzynma (ADAMTS13, Recombinant-Krhn) (for Ohio Only)
    Policy CodePolicy CSOH2026D00131.E
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionDocument cTTP, molecular genetic confirmation of an ADAMTS13 mutation, treatment intent, FDA-label dosing, and hematologist involvement for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OhioApplicable state
    12 monthsInitial and continuation authorization
    3 monthsOn-demand authorization
    J7171Adzynma HCPCS code
    D69.42

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Diagnosis code

    Coverage Criteria

    Initial Prophylactic Therapy

    Covered for initial prophylactic treatment when ALL of the following are met.

    Initial prophylactic therapy

    • Required criteria

      • Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP).
      • Genetic confirmation: ADAMTS13 mutation is confirmed by molecular genetic testing.
      • Treatment purpose: Adzynma is being prescribed for routine prophylactic treatment to prevent thrombotic thrombocytopenic purpura (TTP) events.
      • Dosing: Adzynma dosing is in accordance with the U.S. Food and Drug Administration (FDA)-approved labeling.
      • Specialist involvement: Prescribed by or in consultation with a hematologist.

    Continuation Therapy

    Covered for continuation therapy when ALL of the following are met.

    Continuation therapy

    • Required criteria

      • Prior treatment: Patient has previously received routine prophylactic treatment with Adzynma.
      • Clinical response: Documentation of positive clinical response to Adzynma therapy.
      • Dosing: Adzynma dosing is in accordance with the FDA-approved labeling.
      • Specialist involvement: Prescribed by or in consultation with a hematologist.

    On-Demand Acute TTP Treatment

    Covered for on-demand treatment of an acute TTP event when ALL of the following are met.

    On-demand acute TTP treatment

    • Required criteria

      • Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP).
      • Genetic confirmation: ADAMTS13 mutation is confirmed by molecular genetic testing.
      • Acute event: Adzynma is being prescribed for on-demand treatment of an acute thrombotic thrombocytopenic purpura (TTP) event.
      • Dosing: Adzynma dosing is in accordance with the FDA-approved labeling.

    Coding Information

    HCPCS CodeHCPCS
    J7171Injection, ADAMTS13, recombinant-krhn, 10 IU
    Diagnosis CodeICD-10
    D69.42Congenital and hereditary thrombocytopenia purpura

    Provider Documentation and Authorization Actions

    Prior Authorization

    Initial Prophylaxis Prior Authorization

    Prior authorization is required for initial prophylactic therapy. Document that the patient meets every initial-therapy criterion before requesting coverage.

    • Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP).
    • ADAMTS13 mutation confirmed by molecular genetic testing.
    • Adzynma is prescribed for routine prophylactic treatment to prevent TTP events.
    • Dosing is in accordance with U.S. Food and Drug Administration (FDA)-approved labeling.
    • Prescribed by or in consultation with a hematologist.
    • Requested authorization does not exceed 12 months.
    Prior Authorization

    Continuation Prior Authorization

    Prior authorization is required for continuation of prophylactic therapy. Submit documentation demonstrating prior Adzynma prophylaxis, positive clinical response, and compliance with the continuation criteria.

    Clinical Background

    Adzynma (ADAMTS13, recombinant-krhn) is a recombinant form of endogenous ADAMTS13, a plasma zinc metalloprotease that regulates von Willebrand factor (VWF) activity. ADAMTS13 cleaves large and ultra-large VWF multimers into smaller units, reducing VWF-mediated platelet binding and the propensity to form microthrombi. This policy addresses enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP), including routine prophylaxis to prevent TTP events and on-demand treatment of acute TTP events.

    Definitions

    Adzynma
    ProductAdzynma (ADAMTS13, recombinant-krhn)
    DefinitionA recombinant form of endogenous ADAMTS13.
    RoleADAMTS13 is a plasma zinc metalloprotease that regulates von Willebrand factor activity by cleaving large and ultra-large von Willebrand factor multimers to smaller units.
    Clinical effectCleavage reduces the platelet-binding properties of von Willebrand factor and its propensity to form microthrombi.
    cTTP
    AbbreviationcTTP
    Definition

    Initial Therapy Criteria

    Adzynma Initial Prophylaxis

    Initial prophylactic therapy is covered when ALL of the following are met.

    Adzynma initial prophylaxis

    • Required criteria

      • Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP).
      • Genetic confirmation: ADAMTS13 mutation is confirmed by molecular genetic testing.
      • Treatment purpose: Adzynma is being prescribed for routine prophylactic treatment to prevent thrombotic thrombocytopenic purpura (TTP) events.

    Continuation Therapy Criteria

    Adzynma Continuation Therapy

    Continuation therapy is covered when ALL of the following are met.

    Adzynma continuation therapy

    • Required criteria

      • Prior treatment: Patient has previously received routine prophylactic treatment with Adzynma.
      • Clinical response: Documentation of positive clinical response to Adzynma therapy.
      • Dosing: Adzynma dosing is in accordance with the FDA-approved labeling.
    Policy Summary
    PayerUnitedHealthcare
    PolicyAdzynma (ADAMTS13, Recombinant-Krhn) (for Ohio Only)
    Policy CodePolicy CSOH2026D00131.E
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionDocument cTTP, molecular genetic confirmation of an ADAMTS13 mutation, treatment intent, FDA-label dosing, and hematologist involvement for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Documentation and Authorization ActionsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy Criteria
  1. Specialist involvement: Prescribed by or in consultation with a hematologist.
    • Patient has previously received routine prophylactic treatment with Adzynma.
    • Documentation shows a positive clinical response to Adzynma therapy.
    • Dosing is in accordance with FDA-approved labeling.
    • Prescribed by or in consultation with a hematologist.
    • Requested authorization does not exceed 12 months.
    Prior Authorization

    Acute On-Demand Prior Authorization

    Prior authorization is required for on-demand treatment of an acute TTP event. Document the acute-treatment indication and all applicable clinical, prescribing, dosing, and authorization requirements.

    • Diagnosis of cTTP.
    • ADAMTS13 mutation confirmed by molecular genetic testing.
    • Adzynma is prescribed for on-demand treatment of an acute TTP event.
    • Dosing is in accordance with FDA-approved labeling.
    • Prescribed by or in consultation with a hematologist.
    • Requested authorization does not exceed 3 months.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Initial Prophylaxis Criteria Not Met

    Initial prophylaxis may be denied when the required diagnosis, genetic confirmation, treatment intent, dosing, specialist involvement, or authorization information is absent or does not meet policy requirements.

    • No documented diagnosis of cTTP.
    • No molecular genetic confirmation of an ADAMTS13 mutation.
    • Adzynma is not prescribed for routine prophylactic prevention of TTP events.
    • Dosing is not in accordance with FDA-approved labeling.
    • No prescription by or consultation with a hematologist.
    • Requested authorization exceeds 12 months.
    Denial Risk

    Continuation or Acute-Treatment Criteria Not Met

    Continuation or acute-treatment requests may be denied when required prior treatment, response, acute-event documentation, diagnosis, dosing, specialist involvement, or authorization information is missing or does not meet policy requirements.

    • For continuation: no prior routine prophylactic Adzynma treatment or no documented positive clinical response.
    • For acute on-demand treatment: no documented acute TTP event in a patient with cTTP.
    • No cTTP diagnosis or molecular genetic confirmation of an ADAMTS13 mutation.
    • Dosing is not in accordance with FDA-approved labeling or there is no hematologist prescription or consultation.
    • Requested authorization exceeds 12 months for continuation or 3 months for acute treatment.
    Congenital thrombotic thrombocytopenic purpura.
    Dosing:
    Adzynma dosing is in accordance with the U.S. Food and Drug Administration (FDA)-approved labeling.
  2. Specialist involvement: Prescribed by or in consultation with a hematologist.
  3. Adzynma On-Demand Treatment

    On-demand acute treatment is covered when ALL of the following are met.

    Adzynma on-demand treatment

    • Required criteria

      • Diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP).
      • Genetic confirmation: ADAMTS13 mutation is confirmed by molecular genetic testing.
      • Acute event: Adzynma is being prescribed for on-demand treatment of an acute thrombotic thrombocytopenic purpura (TTP) event.
      • Dosing: Adzynma dosing is in accordance with the FDA-approved labeling.
      • Specialist involvement: Prescribed by or in consultation with a hematologist.
    Specialist involvement: Prescribed by or in consultation with a hematologist.